Allopregnanolone Regulation of Phasic Dopamine Release and Motivated Behavior
ACS Chemical Neuroscience · 2025
DOI: 10.1021/acschemneuro.4c00774 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Minna H McFarland und 2 weiteren Autor:innen. Beteiligte Einrichtung: Bowles Center for Alcohol Studies, Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United S…. Hauptthemen laut MEDLINE: Pregnanolone, Dopamine, Nucleus Accumbens, Motivation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIAAA NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Allopregnanolone, an endogenous neurosteroid that is a potent, positive allosteric modulator of γ-aminobutyric acid type A (GABAA) receptors, has emerged as a compound with considerable potential in the treatment of psychiatric disorders, including substance use disorders and postpartum depression. We previously demonstrated that allopregnanolone dose- and sex-dependently reduced electrically evoked dopamine release in the nucleus accumbens (NAc) of anesthetized male and female rats, which could indicate negative effects on motivation and reward processing. The present study investigated the effects of allopregnanolone on dopamine release and motivated behaviors in awake rats. Using fast-scan cyclic voltammetry, we found that 15 mg/kg allopregnanolone (IP) reduced the frequency of spontaneous dopamine transients in the NAc of freely moving male and female rats. Next, we observed that allopregnanolone (15 mg/kg, IP) produced a robust conditioned place preference in males and females, indicating that allopregnanolone's effects are not aversive despite fewer dopamine transients. Finally, using a sucrose self-administration task, we found that allopregnanolone (7.5 and 15 mg/kg, IP) did not significantly alter response rate, intertrial and interpress intervals, or trial latency in either sex, suggesting that allopregnanolone does not alter motivation or fast motor actions. These results clarify the regulation of dopamine neurotransmission and motivated behavior by allopregnanolone, which has clinical implications for its use as a therapeutic agent to treat various psychiatric disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bowles Center for Alcohol Studies, Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
ORCID-Profile: Donita L Robinson
Förderung
- NIDA NIH HHS
- NIAAA NIH HHS
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
- National Institute on Alcohol Abuse and Alcoholism
- National Institute on Drug Abuse
- Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill
Zitieren
APA
McFarland, M. H., Morrow, A. L., & Robinson, D. L. (2025). Allopregnanolone Regulation of Phasic Dopamine Release and Motivated Behavior. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.4c00774
Vancouver
McFarland MH, Morrow AL, Robinson DL. Allopregnanolone Regulation of Phasic Dopamine Release and Motivated Behavior. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.4c00774
BibTeX
@article{McFarland2025,
author = {McFarland, Minna H and Morrow, A Leslie and Robinson, Donita L},
title = {Allopregnanolone Regulation of Phasic Dopamine Release and Motivated Behavior},
journal = {ACS Chemical Neuroscience},
year = {2025},
doi = {10.1021/acschemneuro.4c00774}
}
EUVIMED